Sandoz : EMA Accepts MAA For Proposed Biosimilar Denosumab
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Sandoz, a Novartis (NVS) division engaged in generic pharmaceuticals and biosimilars, said Thursday that the European Medicines Agency has accepted the marketing authorization applications for proposed biosimilar denosumab for regulatory review.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1144526482-502cd0f081c9408bb9df5e768a5f6efe.jpg "The Stunning Earnings of the Biggest Movie Franchises—See How They Compare")
